{"id":2549,"date":"2025-09-09T08:21:36","date_gmt":"2025-09-09T08:21:36","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=2549"},"modified":"2025-12-08T16:29:36","modified_gmt":"2025-12-08T16:29:36","slug":"omass-therapeutics-partners-with-genentech","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/","title":{"rendered":"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_f1aa96816cc0a26b9d1a5dd01e1e3087\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png 1731w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech-300x105.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech-1024x359.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech-768x269.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech-1000x351.png 1000w\" type=\"image\/png\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Collaboration leverages OMass&#8217; OdyssION<sup>TM<\/sup> platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease<\/li>\n\n\n\n<li>OMass to receive $20 million upfront payment, with potential for more than $400 million in additional milestone payments, as well as tiered royalties on net sales<\/li>\n<\/ul>\n\n\n\n<p>ARC Oxford based OMass Therapeutics (&#8216;OMass&#8217;), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, has entered into an exclusive collaboration and license agreement with Genentech, a member of the Roche Group, for the rights to develop and commercialise OMass&#8217; preclinical oral small molecule program for inflammatory bowel disease.<\/p>\n\n\n\n<p>&#8220;Using our OdyssION<sup>TM<\/sup> platform, we&#8217;ve been able to make significant progress on this novel first-in-class target with a differentiated mechanism of action in inflammatory bowel disease&#8221;, said <strong>Ros Deegan, CEO of OMass Therapeutics<\/strong>. &#8220;Genentech brings a strong legacy of innovation in immunology and world class expertise, making them an ideal partner for this program. We are delighted to be partnering with them and build on the progress we have made to date.&#8221;<\/p>\n\n\n\n<p>&#8220;There are nearly eight million people living with IBD who are in need of innovative treatment approaches&#8221;, said <strong>Boris L. Zaitra, Head of Roche Corporate Business Development<\/strong>. &#8220;Despite recent advancements, there is still a high unmet medical need which fuels our commitment to partnering with companies such as OMass Therapeutics focused on innovation to accelerate potentially transformative medicines and advance science.&#8221;<\/p>\n\n\n\n<p>Under the terms of the agreement, OMass will receive an upfront payment of $20 million, plus additional potential preclinical, development, commercial and net sales milestone payments of more the $400 million. Under the collaboration, OMass will lead the initial preclinical development of the program until candidate selection. Genentech will be responsible for clinical development, regulatory activities, manufacturing and commercialisation. <\/p>\n\n\n\n<p>Founded in 2016, Oxford University Spin-out OMass is the result of a lifetime of scientific research by founder, Oxford University Professor Dam Carol Robinson. In 2023, the company moved to ARC Oxford into a 16,500 sq.ft purpose built space with structural biology lab, chemistry lab, and larger cold room providing the team much more space to work.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n    <section class=\"news-archive \" id=\"block_db4655885fd5c81b50b09518f06cd69b\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png 1200w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-300x169.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1024x576.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-768x432.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1000x563.png 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-475x267.png 475w\" type=\"image\/png\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\" target=\"_self\">\n\t\t\t\tAccession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg 1110w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-300x201.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1024x685.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-768x513.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1000x668.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tChildbase Partnership announces new Garsington Road day nursery opening at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg 2402w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-768x512.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\" target=\"_self\">\n\t\t\t\tOxa Raises $103m in Series D First Close to supercharge Industrial Mobility Automation\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>ARC Oxford based OMass Therapeutics (&#8216;OMass&#8217;), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, has entered into an exclusive collaboration and license agreement with Genentech, a member of the Roche Group, for the rights to develop and commercialise OMass&#8217; preclinical oral small molecule program for inflammatory [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":2550,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22],"tags":[6210,50841],"class_list":["post-2549","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-life-science-and-health","tag-member-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease - ARC Oxford<\/title>\n<meta name=\"description\" content=\"ARC Oxford based OMass Therapeutics has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialise OMass&#039; preclinical oral small molecule program for inflammatory bowel disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease - ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"ARC Oxford based OMass Therapeutics has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialise OMass&#039; preclinical oral small molecule program for inflammatory bowel disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-09T08:21:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T16:29:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1731\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"nataliegelder\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"nataliegelder\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/\"},\"author\":{\"name\":\"nataliegelder\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\"},\"headline\":\"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease\",\"datePublished\":\"2025-09-09T08:21:36+00:00\",\"dateModified\":\"2025-12-08T16:29:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/\"},\"wordCount\":362,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png\",\"keywords\":[\"Life science and Health\",\"Member news\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/\",\"name\":\"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease - ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png\",\"datePublished\":\"2025-09-09T08:21:36+00:00\",\"dateModified\":\"2025-12-08T16:29:36+00:00\",\"description\":\"ARC Oxford based OMass Therapeutics has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialise OMass' preclinical oral small molecule program for inflammatory bowel disease.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png\",\"width\":1731,\"height\":607,\"caption\":\"OMass Therapeutics partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/oxford\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\",\"name\":\"nataliegelder\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"caption\":\"nataliegelder\"},\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/nataliegelder\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease - ARC Oxford","description":"ARC Oxford based OMass Therapeutics has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialise OMass' preclinical oral small molecule program for inflammatory bowel disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/","og_locale":"en_US","og_type":"article","og_title":"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease - ARC Oxford","og_description":"ARC Oxford based OMass Therapeutics has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialise OMass' preclinical oral small molecule program for inflammatory bowel disease.","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/","og_site_name":"ARC Oxford","article_published_time":"2025-09-09T08:21:36+00:00","article_modified_time":"2025-12-08T16:29:36+00:00","og_image":[{"width":1731,"height":607,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png","type":"image\/png"}],"author":"nataliegelder","twitter_card":"summary_large_image","twitter_misc":{"Written by":"nataliegelder","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/"},"author":{"name":"nataliegelder","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3"},"headline":"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease","datePublished":"2025-09-09T08:21:36+00:00","dateModified":"2025-12-08T16:29:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/"},"wordCount":362,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png","keywords":["Life science and Health","Member news"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/","name":"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease - ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png","datePublished":"2025-09-09T08:21:36+00:00","dateModified":"2025-12-08T16:29:36+00:00","description":"ARC Oxford based OMass Therapeutics has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialise OMass' preclinical oral small molecule program for inflammatory bowel disease.","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png","width":1731,"height":607,"caption":"OMass Therapeutics partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3","name":"nataliegelder","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","caption":"nataliegelder"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/nataliegelder\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/2549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=2549"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/2549\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/2550"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=2549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=2549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=2549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}